MyoHtutMD

Hematologic Oncology

Physician

Overview of Dr. Htut

Dr. Myo Htut is an oncologist in Duarte, CA and is affiliated with City of Hope Comprehensive Cancer Center. He received his medical degree from University Institute of Medicine 1 and has been in practice 21 years. He is one of 222 doctors at City of Hope Comprehensive Cancer Center who specialize in Oncology. He has more than 30 publications and over 500 citings.

Office
1500 Duarte Rd
Duarte, CA 91010
Book by Phone+1(520) 729-9915

Fax+1 626-408-3911

Education & Training

University of ColoradoFellowship, Hematology and Medical Oncology, 2007 - 2009
MedStar Health/Harbor HospitalResidency, Internal Medicine, 1999 - 2002
University Institute of Medicine 1Class of 1996

Certifications & Licensure

CA State Medical License 2002 - 2025
CO State Medical License 2008 - 2011
MI State Medical License 2002 - 2009
PA State Medical License 2004 - 2006
American Board of Internal Medicine Internal Medicine

Clinical Trials

Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload Start of enrollment: 2010 Jul 01
Terminated
Phase 2
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Start of enrollment: 2010 Dec 01
Completed
Phase 1
CT Antigen TCR-Engineered T Cells for Myeloma Start of enrollment: 2013 Oct 15
Terminated
Phase 1, Phase 2
Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma Start of enrollment: 2018 Feb 01
Completed
Phase 1, Phase 2
CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma Start of enrollment: 2019 Apr 23
Recruiting
Phase 1
MM CAR-T to Upgrade Response BMTCTN1902 Start of enrollment: 2022 Jan 05
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

215 citations
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Fol...
Thomas Martin, Saad Z Usmani, Jesus G Berdeja, Mounzer Agha, Adam D Cohen
Journal of Clinical Oncology. 2023-02-20
28 citations
A phase 1 dose‐escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma
Ajai Chari, Myo Htut, Jeffrey A. Zonder, Joseph W. Fay, Andrzej Jakubowiak
Cancer. 2016-11-01
173 citations
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
Maria-Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, Albert Oriol, David Simpson
The Lancet. Haematology. 2019-07-18

Journal Articles

Twice‐Weekly Ixazomib in Combination with Lenalidomide‐Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
Myo Htut, Michaela Liedtke, Stephen D Smith, Craig C Hofmeister, Rachid Baz, Paul G Richardson, Cara A Rosenbaum, David H Vesole, Ajai Chari, Jesus G Berdeja, Noopur Raje, British Journal of Haematology

Abstracts/Posters

Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Myo Htut, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Repurposing Leflunomide for Relapsed/Refractory Multiple Myeloma: Final Analysis of a Phase 1 Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
CD84: A Potential Novel Therapeutic Target in Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

OncLive® Presents State of the Science Summit™: Diagnosis, Management, and Treatment of Multiple Myeloma, and Myeloproliferative NeoplasmApril 11th, 2018
Stemline Announces Seven Presentations, Including Oral Presentation of Updated SL-401 Phase 2 BPDCN Data, at Upcoming ASH MeetingDecember 2nd, 2016